Logo image of GCTK

GLUCOTRACK INC (GCTK) Stock Fundamental Analysis

NASDAQ:GCTK - Nasdaq - US45824Q7051 - Common Stock - Currency: USD

0.1492  +0 (+2.9%)

Premarket: 0.1469 0 (-1.54%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to GCTK. GCTK was compared to 189 industry peers in the Health Care Equipment & Supplies industry. GCTK has a bad profitability rating. Also its financial health evaluation is rather negative. GCTK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GCTK had negative earnings in the past year.
GCTK had a negative operating cash flow in the past year.
In the past 5 years GCTK always reported negative net income.
In the past 5 years GCTK always reported negative operating cash flow.
GCTK Yearly Net Income VS EBIT VS OCF VS FCFGCTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

GCTK has a Return On Assets of -380.93%. This is amonst the worse of the industry: GCTK underperforms 97.35% of its industry peers.
Industry RankSector Rank
ROA -380.93%
ROE N/A
ROIC N/A
ROA(3y)-130.51%
ROA(5y)-147.55%
ROE(3y)-220.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GCTK Yearly ROA, ROE, ROICGCTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K -5K 10K 15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GCTK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GCTK Yearly Profit, Operating, Gross MarginsGCTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for GCTK has been increased compared to 1 year ago.
Compared to 5 years ago, GCTK has more shares outstanding
Compared to 1 year ago, GCTK has an improved debt to assets ratio.
GCTK Yearly Shares OutstandingGCTK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
GCTK Yearly Total Debt VS Total AssetsGCTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -38.32, we must say that GCTK is in the distress zone and has some risk of bankruptcy.
GCTK's Altman-Z score of -38.32 is on the low side compared to the rest of the industry. GCTK is outperformed by 91.53% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -38.32
ROIC/WACCN/A
WACCN/A
GCTK Yearly LT Debt VS Equity VS FCFGCTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 4.52 indicates that GCTK has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.52, GCTK is in the better half of the industry, outperforming 71.96% of the companies in the same industry.
A Quick Ratio of 4.52 indicates that GCTK has no problem at all paying its short term obligations.
GCTK's Quick ratio of 4.52 is fine compared to the rest of the industry. GCTK outperforms 76.72% of its industry peers.
Industry RankSector Rank
Current Ratio 4.52
Quick Ratio 4.52
GCTK Yearly Current Assets VS Current LiabilitesGCTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

GCTK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -94.02%.
EPS 1Y (TTM)-94.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GCTK Yearly Revenue VS EstimatesGCTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 200K 400K 600K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GCTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GCTK Price Earnings VS Forward Price EarningsGCTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GCTK Per share dataGCTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -20 -40 -60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GCTK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GLUCOTRACK INC

NASDAQ:GCTK (5/20/2025, 8:00:01 PM)

Premarket: 0.1469 0 (-1.54%)

0.1492

+0 (+2.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.43%
Inst Owner Change54.86%
Ins Owners0.16%
Ins Owner Change0.26%
Market Cap3.82M
AnalystsN/A
Price TargetN/A
Short Float %3.32%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-65.81
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0
BVpS-0.51
TBVpS-0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -380.93%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-130.51%
ROA(5y)-147.55%
ROE(3y)-220.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.52
Quick Ratio 4.52
Altman-Z -38.32
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)5.42%
Cap/Depr(5y)35.05%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-94.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.66%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-104.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-75.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-75.86%
OCF growth 3YN/A
OCF growth 5YN/A